Maximum Tolerated Dose (MTD) Cycle 1 (within the first 4 weeks) [clinicaltrials_resource:4a57afd6bcc239220dc4fd4349fdffb4]
Administered intravenously once weekly for 4 weeks (1 cycle).
In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Maximum Tolerated Dose (MTD) Cycle 1 (within the first 4 weeks) [clinicaltrials_resource:4a57afd6bcc239220dc4fd4349fdffb4]
Administered intravenously once weekly for 4 weeks (1 cycle).
In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles.
Bio2RDF identifier
4a57afd6bcc239220dc4fd4349fdffb4
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4a57afd6bcc239220dc4fd4349fdffb4
measure [clinicaltrials_vocabulary:measure]
Maximum Tolerated Dose (MTD)
time frame [clinicaltrials_vocabulary:time-frame]
Cycle 1 (within the first 4 weeks)
description
Administered intravenously onc ...... to receive additional cycles.
identifier
clinicaltrials_resource:4a57afd6bcc239220dc4fd4349fdffb4
title
Maximum Tolerated Dose (MTD) Cycle 1 (within the first 4 weeks)
@en
type
label
Maximum Tolerated Dose (MTD) C ...... 7afd6bcc239220dc4fd4349fdffb4]
@en